Engineered TCR and CAR Immunotherapeutics 2015

Publisher: La Merie Publishing
Pages: 201
Format: PDF
Product Line:
LMP Full Report
Product Code: LMFR0015
Release Date: March of 2015

2,450.00 €
(Discount: 20.00%)
1,960.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Engineered TCR and CAR Immunotherapeutics 2015:

A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & CTLs

The engineered T cell receptor (TCR) for targeting of intracellular targets not druggable by conventional antibody technologies, and specifically targeted engineered T cells are two of the most promising emerging technologies in immuno-oncology apart from immune checkpoint modulators. The relevance of TCR targeting and engineered T cells is reflected by impressive clinical results with CD19 chimeric antigen receptor (CAR) T cells and outstanding partnering and financing deals concluded within the last two years.

Leveraging the power of T cells by cellular and recombinant immunotherapeutics

 

Intra-cellular Targets

Cell surface targets

Cellular

TCR T Cells

CAR T Cells
(autologous/allogeneic)

Recombinant

Bispecific TCR-anti-CD3
(e.g. ImmTACs)

Bispecific antibodies
(incl. anti-CD3)

 

This report „Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs“ as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies.

However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities.

Download Sample Pages: Engineered TCR and CAR Immunotherapeutics 2015

This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.

What will you find in the report?

  • Profiles of TCR and CAR immunotherapeutics in development;
  • Competitor analysis of CD19 CAR T cells;
  • Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value;
  • Target analysis of TCR T cells in R&D;
  • CAR T Cell pipeline in hematology;
  • CAR T Cell pipeline in solid tumors;
  • Allogeneic TCR and CAR T cells in R&D;
  • Universal antibody-targeted CAR T cells and NK cells;
  • Pipeline of most promising TILs, NK cells, DLIs and CTLs;
  • Technologies needed for next generations of TCR and CAR immunotherapeutics;
  • Profiles of biotechnology companies incl. financing and licensing/partnering;
  • Profiles and scope of interest of Big Pharma/Biotech for TCRs & CARs;
  • Stakeholder analysis (established, emerging, non-US, technology providers);
  • Potential of alternative adoptive immunotherapies (NKs, TILs, CTLs, DLIs);
  • Analysis of major partnering deals (Big pharma & biotech);
  • Economic terms of pharma-biotech deals;
  • Opportunities for biotech-biotech deals in the TCR and CAR field;
  • Potential to raise private money with TCR and CAR technologies;
  • Success in initial public offerings and follow on offerings with TCRs and CARs;
  • Limitations and hurdles with current TCR and CAR immunotherapeutics;
  • Opportunities for novel TCR and CAR immunotherapeutics;
  • Pricing of TCR and CAR immunotherapeutics;
  • Aspects of manufacturing and commercialization.

Who will benefit from the report?

  • Venture capital, private equity and investment managers;
  • Financial analysts;
  • CFO;
  • Business development and licensing (BDL) specialists;
  • Marketing managers;
  • CEO, COO and managing directors;
  • Corporate strategy, product and portfolio analysts and managers;
  • Chief Technology Officer;
  • Cell technology and manufacturing specialists;
  • Clinical and preclinical development specialists.

Engineered TCR and CAR Immunotherapeutics 2015:

A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs and CTLs

TABLES of the REPORT

Table 1            Open Phase I/II Clinical Trials with Adaptimmune’s NY-ESOc259T
Table 2            Planned clinical study at Dana Farber Cancer Institute with autologous T-cells expressing chimeric NKG2D receptor
Table 3            Pipeline of TCR T-Cell Product Candidates from Companies
Table 4            Pipeline of CD19 CAR T-cell product candidates from Companies
Table 5            Pipeline of Hematologic CAR T-cell product candidates from Companies
Table 6            Pipeline of Solid Tumor CAR T-cell product candidates from Companies
Table 7            Pipelines of NK cells, TILs, DLIs & CTLs from Companies
Table 8            Open Phase I/II Clinical Trials with Adaptimmune’s NY-ESOc259T
Table 9            Bellicum’s Pipeline of Cellular Product Candidates
Table 10          Cardio3 BioSciences‘ R&D Pipeline of CAR T-Cells
Table 11          Cellectis R&D Pipeline of UCARTs
Table  12         Early clinical trials at PLA General Hospital with autologous CAR T cells
Table 13          Conkwest’s R&D pipeline of Natural Killer Cell-derived Product Candidates
Table 14          Goals and terms of Immunocore’s partnering deals for ImmTAC technology
Table 15          CAR Pipeline of ZIOPARM Oncology & Intrexon & MD Anderson
Table 16          Profiles of Juno’s lead CD19-directed T-cell product candidates
Table 17          Juno’s Pipeline of CAR and TCR T cell product candidates
Table 18          Kite Pharma’s Pipeline of CAR and TCR T cell product candidates
Table 19          Lion’s Pipeline of autologous Tumor Infiltration Lymphocytes
Table 20          Clinical studies at MD Anderson with 2nd generation CD19 CAR T-cells co-activating via chimeric CD3z/CD28
Table 21          Takara Bio’s Pipeline of TCR and CAR T cell product candidates
Table 22          Clinical study in Singapore with 3rd generation universal ACTR T-cells CD16V-BB-ζ  in combination with rituximab
Table 23          Novartis‘ Pipeline of autologous CAR T-cell product candidates
Table 24          Major terms of collaboration between Cellectis and Pfizer
Table 25          Major terms of collaboration between Cellectis and Servier
Table 26          Competitive Profiles of the five most advanced CAR / TCR T-Cell Companies
Table 27          Competitive Profiles of emerging or non-US CAR / TCR T-Cell Companies
Table 28          Companis providing technology in the CAR T Cell Therapy field
Table 29          TCR and CAR Deals between Pharma and Biotech
Table 30          Scope of Interest of Pharma Deals for TCR & CAR Immunotherapeutics
Table 31          Alternative T Cell and Natural Killer Cell Immunotherapeutics
Table 32          TCR and CAR Deals between Pharma and Biotech
Table 33          Economic Terms of TCR and CAR Deals between Pharma and Biotech
Table 34          Biotech – Biotech Deals in the field of TCR and CAR Immunotherapeutics
Table 35          Private Financing Rounds of Companies with TCR or CAR Immunotherapeutics
Table 36          Public Offering & Market Capitalization of Companies with TCR or CAR Immunotherapeutics
Table 37          Opportunities for novel TCR and CAR Immunotherapeutics


Engineered TCR and CAR Immunotherapeutics 2015:

A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs and CTLs

Corporate Stakeholders of TCR, CAR, T-Cells, DLIs, TILs and combinations thereof

Adaptimmune
Altor Biosciences
Amgen
Applied Immune Technologies
AstraZeneca
Autolus
Bellicum Pharmaceuticals
Bluebird bio
Cardio3 BioSciences
Celgene
Cellectis
Cellular BioMedicine Group (CBMG)
Conkwest
CRISPR Therapeutics
CytomX
Editas Medicine
Eli Lilly
Eureka Therapeutics
GlaxoSmithKline
Immunocore
Intellia Therapeutics
Intrexon
Janssen (J&J)
Juno Therapeutics
Kite Pharma
Lion Biotechnologies
Medigene
Nextera
Novartis
Pfizer
Roche
Servier
Sorrento Therapeutics
Takara Bio
Transposagen Biopharmaceuticals
Unum Therapeutics
ZIOPHARM Oncology

 


Engineered TCR and CAR Immunotherapeutics 2015:

A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs and CTLs

TABLE OF CONTENTS

1          Introduction  

2          Executive Summary

3          Profiles of TCR & CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs 

3.1       TCR Fusion Proteins & Antibodies  
- ALT-801        
- IMCgp100  
- ESK1 / ESKM3.2     

3.2       Autologous TCR T Cells for Solid Tumors & Hematologic Malignancies 
- NY-ESOc259T 
- JCAR016
- TBI-1201       
- TBI-1301       
- BPX-701       

3.3       CD19 CAR T Cells   
- CTL019         
- HuCART19 (HuCTL019)    
- JCAR015       
- JCAR017       
- JCAR014       
- KTE-C19       
- CD19-CAR T cells (Takara) 
- BPX-401       

3.4       Other Autologous CAR T Cells for Hematological Malignancies  
- CART123      
- CM-CS1  

3.5       Autologous CAR T Cells for Solid Tumors 
- G2-CAR.OX4028.z.ICD19 
- BPX-601       
- CAR-NKp30/B7H6  
- CART-EGFRvIII     
- CART-meso T cells   

3.6       Allogeneic CAR T Cells       
- UCART19     
- UCART38     
- UCART123   
- UCARTCS1  

3.7       Universal CAR T cells          
- ATTCK20     

3.8       NK Cells, TILs, DLIs & CTLs         
- Natural Killer (NK) cells: Neukoplast / NK-92       
- NK cells: CD16-Neukoplast 
- NK cells: NK-92.ErbB2/Her2          
- Tumor Infiltrating Lymphocytes (TILs): LN-144 (Contego)          
- Donor Lymphocyte Infusion (DLI): BPX-501        
- Cytotoxic T-Lymphocytes (CTLs): EBV-CTL   

4          Pipeline Analysis       
4.1       TCR Antibodies, Fusion Proteins and TCR-like Antibodies          
4.2       TCR T-Cells  
4.3       CD19 CAR T Cells   
4.4       Other CAR T Cells for Hematological Malignancies          
4.5       Other CAR T Cells for Solid Tumors          
4.6       Allogeneic TCR & CAR T Cells      
4.7       Universal, antibody-targeted CAR T Cells  
4.8       Natural Killer cells (NK cells), Tumor Infiltrating Lymphocytes (TILs), Donor Lymphocyte Infusions (DLIs) and Cytotoxic T Lymphocytes (CTLs)    

5          Technology Companies       
5.1       Adaptimmune
5.2       Altor Bioscience        
5.3       Applied Immune Technologies (AIT)          
5.4       Atara Biotherapeutics
5.5       Autolus          
5.6       Bellicum Pharmaceuticals     
5.7       Bluebird bio   
5.8       Cardio3 BioSciences 
5.9       Cellectis         
5.10     Cellular Biomedicine Group (CBMG)         
5.11     Conkwest      
5.12     CRISPR Therapeutics           
5.13     CytomX         
5.14     Editas Medicine        
5.15     Eureka Therapeutics  
5.16     Immunocore  
5.17     Intellia Therapeutics  
5.18     Intrexon, ZIOPHARM Oncology & MD Anderson           
5.19     Juno Therapeutics      
5.20     Kite Pharma   
5.21     Lion Biotechnologies
5.22     MD Anderson Cancer Center           
5.23     Medigene       
5.24     Nextera          
5.25     Sorrento Therapeutics           
5.26     Takara Bio     
5.27     Transposagen Biopharmaceuticals    
5.28     Unum Therapeutics   

6          Pharmaceutical Companies   
6.1       Amgen           
6.2       AstraZeneca  
6.3       Celgene          
6.4       Eli Lilly          
6.5       GlaxoSmithKline      
6.6       Janssen Biotech         
6.7       Novartis         
6.8       Pfizer 
6.9       Roche 
6.10     Servier

7          Stakeholder Analysis
7.1       TCR Focused Companies     
7.2       Established CAR (& TCR) T Cell Companies         
7.3       Emerging and/or non-US based CAR (& TCR) T Cell Companies
7.4       Technology Providers
7.5.      Pharma Companies in the Field        
7.6       Companies with Alternative Adoptive Cell Therapies: NK Cells, TILs, DLIs & CTLs  

8          Selected Technology Profiles

8.1       Genome Editing Technologies         
- Allogeneic multichain chimeric Antigen Receptor (mcCAR) T-cells         
- CAR T cells and multiplex gene editing (bluebird bio)       
- Genome Editing Technology (Transposagen)

8.2       Switch Technologies 
- Inducible Caspase 9 and inducible MyD88/CD40 Switch Systems           
- RheoSwitch Therapeutic System (RTS) technology

8.3       Non-Viral Gene Transfer      
- Sleeping Beauty 

8.4       Next Generation CAR T Cell Technologies 
- Juno Therapeutics‘ CAR Technologies 

8.5       Engineered TCR T Cells       
- TCR Engineered T Cell Technology (Adaptimmune)   

8.6       Special Cases of CAR T Cell Construcs      
- Oncyte CAR T Cell Constructs        
- Universal Antibody-Coupled T-cell Receptor (ACTR) technology

9          Business Perspective on TCR and CAR Immunotherapeutics        
9.1       Deals  
9.2       Private Financing Rounds     
9.3       Public Offerings and Market Capitalization of Companies with TCR or CAR Immunotherapeutics    

10        Outlook for TCR and CAR Immunotherapeutics   
10.1     Limitations and Hurdles with current CAR T Cell Therapies         
10.2     Opportunities for Novel TCR and CAR Immunotherapeutics       
10.3     Pricing of CAR and TCR T Cell Products   
10.4     Manufacturing and Commercialization    

11        References     



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top